Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen accrued Sales Deductions Liability — Balance Sheet Ending Reserve ($M) ($M)
Form 10-Q / 10-K Other Current Liabilities Note & MD&A GTN Rollforward
Latest, FY2025
10,606
Period ended Dec 31, 2025
Change on a year earlier
+26.2%
8,405 in FY2024
History
13 years
Since FY2013
Sources
11
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Accrued Sales Deductions Liability — Balance Sheet Ending Reserve ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10,606 | +26.2% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 8,405 | +15.6% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 7,271 | +21.5% | Form 10-K (filed 2025-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 5,986 | +15.7% | Form 10-K (filed 2024-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 5,174 | +7.8% | Form 10-K (filed 2023-02-09) ↗ |
| FY2020 | Dec 31, 2020 | 4,801 | +23.7% | Form 10-K (filed 2022-02-16) ↗ |
| FY2019 | Dec 31, 2019 | 3,880 | +22.4% | Form 10-K (filed 2021-02-09) ↗ |
| FY2018 | Dec 31, 2018 | 3,170 | +41.1% | Form 10-K (filed 2019-02-13) ↗ |
| FY2017 | Dec 31, 2017 | 2,247 | +19.9% | Form 10-K (filed 2019-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 1,874 | +26.1% | Form 10-K (filed 2018-02-13) ↗ |
| FY2015 | Dec 31, 2015 | 1,486 | +7.8% | Form 10-K (filed 2017-02-14) ↗ |
| FY2014 | Dec 31, 2014 | 1,379 | +10.5% | Form 10-K (amgn-12312017x10k.htm, filed 2018-02-13) ↗ |
| FY2013 | Dec 31, 2013 | 1,248 | – | Form 10-K (amgn-12312015x10k.htm, filed 2016-02-16) ↗ |
Breakdown
What makes up accrued sales deductions liability — balance sheet ending reserve ($m)
- Accrued Rebates Reserve — Ending Balance ($M)8,839 · FY2025
- Accrued Wholesaler Chargebacks Reserve — Ending Balance ($M)1,298 · FY2025
- Accrued Other Deductions Reserve (Cash Discounts & Co-Pay) — Ending Balance ($M)469 · FY2025
- Accrued Product Sales Returns Liability (legacy standalone disclosure) ($M)548 · FY2022
- Provisions for Product Sales Returns as % of Gross Product Sales (%)1.0% · FY2025
- Favorable GTN Adjustments Related to Prior Period Sales (legacy disclosure) ($M)0 · FY2020
- Operating Cash Flow — Change in Accrued Sales Incentives & Allowance ($M)2,065 · FY2025
Cite this data
StockData. (2026). Amgen Accrued Sales Deductions Liability — Balance Sheet Ending Reserve ($M) ($M), annual FY2013–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/gtn_liab_tot
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.